MX 35 monoclonal antibody

shows strong reactivity with more than 90% of epithelial ovarian cancers; from a clinial trial involving the pharmacokinetics, biodistribution & intraoperative radioimmunodetection of radiolabeled MX 35 in patients with advanced ovarian cancer

Also Known As:

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 10/01/1993 - "MAb MX 35 localizes well to tumor in selected patients with ovarian cancer, and MAb uptake can be reliably quantitated in vivo with the hand-held intraoperative gamma counter."
2.	Neoplasms (Cancer) 10/01/1993 - "MAb MX 35 localizes well to tumor in selected patients with ovarian cancer, and MAb uptake can be reliably quantitated in vivo with the hand-held intraoperative gamma counter."
3.	Ovarian Epithelial Carcinoma 10/01/1993 - "Murine monoclonal antibody (MAb) MX 35 shows strong homogeneous reactivity with more than 90% of epithelial ovarian cancers. "

Related Drugs and Biologics

1.	Monoclonal Antibodies